Speech biomarker companies for CNS clinical trials (2026)
Companies whose own website offers speech or voice biomarkers for clinical trials or clinical studies, with named CNS indications. Listed in alphabetical order, with no ranking. Published by Cephalgo, a speech biomarker company in Strasbourg, France, which is one of the companies listed. To add or correct a row, write to contact@cephalgo.com.
Last checked: 18 November 2026 · Alphabetical order, no ranking
Who offers speech biomarkers for CNS trials
Country, offer and named indications as each company states them on its own website. Follow the source link to check a row.
| Company | Country | What they publicly offer | Indications they name | Source |
|---|---|---|---|---|
| acceXible | SpainUrduliz | Speech-based assessments for clinical trial pre‑screening, longitudinal monitoring and digital endpoints. | Early cognitive decline, preclinical dementia | accexible.com/en |
| Cambridge CognitionWinterlight Labs | United KingdomCambridge | Voice analysis for trial sponsors: standardised speech samples turned into acoustic and linguistic measures, with automated scoring of verbal cognitive tasks beside CANTAB, on browsers, tablets and smartphones. | Alzheimer’s disease, mild cognitive impairment, schizophrenia and psychosis, depression, ALS, frontotemporal dementia | Offer: cambridgecognition.com/ |
| Canary Speech | United StatesProvo, Utah | Voice biomarker technology for clinical trials, from a short audio sample recorded on a smartphone or tablet. | Multiple sclerosis, Parkinson’s disease, Huntington’s disease, anxiety, depression, dementia | Offer: canaryspeech.com/ |
| CephalgoPublisher of this page | FranceStrasbourg | Speech readings on the scale a trial already uses, from recordings already held, site visits or home sessions; also review of recorded rating interviews. | Alzheimer’s, Parkinson’s, Huntington’s, ALS | cephalgo.com/cns |
| Cumulus Neuroscience | United KingdomBelfast | A multi-modal platform for CNS clinical studies that measures speech (rate, output and pausing) beside cognition, EEG, mood and sleep, in clinic or at home. | Alzheimer’s disease | cumulusneuro.com/ |
| ki:elements | GermanySaarbrücken | Speech biomarkers for clinical trials from short spoken tasks by telephone, app or browser, for remote pre‑screening and longitudinal tracking. | Alzheimer’s, ALS/MND, Parkinsonian syndromes, major depressive disorder, schizophrenia | ki-elements.de |
| Koneksa | United States | A digital endpoint platform for clinical trials whose configurable measures include speech and voice biomarkers. | Parkinson’s disease | Offer: koneksahealth.com/ |
| LANGaware | United States | Speech and voice biomarker software for mild cognitive impairment, Alzheimer’s disease and depression, offered for clinical trial recruitment and for tracking change over time. | Mild cognitive impairment, Alzheimer’s disease, depression | Offer: langaware.com/ |
| Linus HealthAural Analytics | United StatesBoston | Digital cognitive assessments for clinical trials, including voice-based tasks scored for acoustic, semantic and timing measures. | Alzheimer’s disease, mild cognitive impairment, Parkinson’s disease, ALS | linushealth.com/ |
| Modality.AI | United StatesSan Francisco | A conversational assessment platform for clinical trials that measures speech, facial expression and movement, in clinic or remotely. | ALS, Parkinson’s disease, schizophrenia, depression, autism | modality.ai |
| Novoic | United KingdomLondon | Software that assesses cognition from speech, with a dashboard for trial screening and a speech API. Browser-based, on any smart device. | Alzheimer’s disease, including early and preclinical stages; mild cognitive impairment | novoic.com; head office: UK Companies House |
| Redenlab | AustraliaMelbourne | Speech analytics for industry-run clinical trials, in clinic or remote, including virtual trials for Phase 0 to IV studies. | Alzheimer’s disease, multiple sclerosis, ALS, frontotemporal dementia, Parkinson’s disease, Huntington’s disease, ataxia, neurodevelopmental disorders, depression | redenlab.com |
| Videra Health | United States | A clinical trial observation suite that analyses captured video, voice and movement, with digital endpoints co-developed with sponsors. | Tardive dyskinesia | viderahealth.com/life-sciences/clinical-trials |
Listed: companies whose own website states that they offer speech or voice biomarkers for clinical trials or clinical studies run by sponsors, and that name at least one CNS indication. A product validated only in the company’s own trials does not count, and neither do consumer, telehealth, automotive or contact-centre offers. Where a company has been acquired, it is listed under its current owner with the brand in brackets. Rows use the company’s own words where possible and carry no ranking. Where a website gives no head office, it comes from the national company register. The list may not be complete. To add or correct a row, write to contact@cephalgo.com.
What to ask any provider
The same questions apply to every company on this list, Cephalgo included.
- Which clinical scale does the reading land on?
- Can it read recordings the trial already holds, as well as site visits and home sessions?
- What happens when phones or their software change during the study?
- Which named features sit behind each reading?
- How is each study language calibrated?
- Where is the data hosted, and which documents does your QA team receive?
- How is the work priced, and what does the price include?
- What evidence is available in your indication and population, and where is it published?
- How does the provider support regulatory interactions, such as FDA meetings or EMA qualification advice?
Data protection and hosting
Four points shape how speech is collected and handled in a trial.
Speech is health data
Speech recorded to measure health is a special category of personal data under Article 9 of the GDPR. Sponsors run a data protection impact assessment and sign an Article 28 data processing agreement with the provider.
Where data is hosted
Under Chapter V of the GDPR, a transfer of personal data outside the EU needs a legal basis, such as an adequacy decision or standard contractual clauses. Ask each provider where audio and readings are stored and processed.
Studies in the United States
Sponsors running studies in the United States will ask how a provider handles HIPAA where it applies, and whether its systems meet 21 CFR Part 11 for electronic records and signatures.
Many languages in one trial
Multinational trials often rate the same scale in several languages at once. Speech differs by language, so ask how tasks, quality rules and calibration are set in each study language.
Speech biomarker companies
Which companies offer speech biomarkers for CNS clinical trials?
Companies whose own website offers speech or voice biomarkers for clinical trials or clinical studies, with named CNS indications, include acceXible (Spain), Cambridge Cognition with Winterlight Labs (United Kingdom), Canary Speech (United States), Cephalgo (France), Cumulus Neuroscience (United Kingdom), ki:elements (Germany), Koneksa (United States), LANGaware (United States), Linus Health with Aural Analytics (United States), Modality.AI (United States), Novoic (United Kingdom), Redenlab (Australia) and Videra Health (United States). Last checked on 18 November 2026.
How was this list made?
Cephalgo published this list and is one of the companies on it. A company is listed when its own website states that it offers speech or voice biomarkers for clinical trials or clinical studies run by sponsors, and names at least one CNS indication. A product validated only in the company’s own trials does not count, and neither do consumer, telehealth, automotive or contact-centre offers. Rows are in alphabetical order, with no ranking. The list may not be complete. To add or correct a row, write to contact@cephalgo.com.
Where is speech data from a trial hosted?
Speech recorded to measure health is health data under Article 9 of the GDPR. Where audio and readings are stored and processed is set by each provider and each contract. Ask every provider where data is hosted and on what legal basis any transfer outside the EU takes place. For studies in the United States, sponsors will also ask how the provider addresses HIPAA and 21 CFR Part 11.
What should a sponsor ask a speech biomarker provider?
Ask which clinical scale the reading lands on, where the audio comes from, what happens when phones or their software change, which named features sit behind each reading, how each language is calibrated, how data is protected, what the price includes, what evidence exists for your indication and population, and how the provider supports regulatory interactions. The full checklist sets out eleven questions and why each one matters.